Showing results (31-40 of 394) with videos related to
Sort By:
Pageof 40
Expert Opinion on Pharmacotherapy|November 22, 2011
Treating chronic lymphocytic leukemia with thalidomide and lenalidomideKrzysztof Giannopoulos, Daniel Mertens, Stephan StilgenbauerClinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 14, 2010
Immunoglobulin heavy chain variable gene usage and (super)-antigen drive in chronic lymphocytic leukemiaAndreas Bühler, Thorsten Zenz, Stephan StilgenbauerCancer Treatment Reviews|January 13, 2017
Front-line treatment of CLL in the era of novel agentsTadeusz Robak, Stephan Stilgenbauer, Alessandra TedeschiCurrent Drug Targets|November 1, 2006
Genetics, gene expression, and targeted therapies in chronic lymphocytic leukemiaDirk Winkler, Hartmut Döhner, Stephan StilgenbauerSeminars in Oncology|April 18, 2006
Risk stratification in chronic lymphocytic leukemiaTill Seiler, Hartmut Döhner, Stephan StilgenbauerLeukemia|March 27, 2019
Short telomeres are associated with inferior outcome, genomic complexity, and clonal evolution in chronic lymphocytic leukemiaBilly Michael Chelliah Jebaraj, Eugen Tausch, Dan A Landau, et al.Cell Communication and Signaling : CCS|May 20, 2025
GPR15LG binds CXCR4 and synergistically modulates CXCL12-induced cell signaling and migrationDan Pascal Jean Albers, Sofya Novikova, Julio Vieyto-Nuñez, et al.Cancers|January 8, 2023
To β or Not to β: How Important Is β-Catenin Dependent and Independent WNT Signaling in CLL?Karol D Urbanek, Stephan Stilgenbauer, Daniel MertensClinical Advances in Hematology & Oncology : H&O|January 4, 2011
Clinical roundtable monograph. New alternatives in CLL therapy: managing adverse eventsAsher Chanan-Khan, Thomas Kipps, Stephan StilgenbauerBlood Reviews|March 26, 2011
Importance of genetics in chronic lymphocytic leukemiaThorsten Zenz, Daniel Mertens, Hartmut Döhner, et al.Pageof 40